These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

973 related items for PubMed ID: 16516356

  • 1. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 2. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.
    Even-Or O, Joseph A, Itskovitz-Cooper N, Samira S, Rochlin E, Eliyahu H, Goldwaser I, Balasingam S, Mann AJ, Lambkin-Williams R, Kedar E, Barenholz Y.
    Vaccine; 2011 Mar 16; 29(13):2474-86. PubMed ID: 21251901
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, Spira J, Goldwaser I, Ellis R, Barenholz Y.
    Vaccine; 2010 Sep 07; 28(39):6527-41. PubMed ID: 20412874
    [Abstract] [Full Text] [Related]

  • 4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 5. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 6. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 7. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.
    Microbiol Immunol; 2008 Feb 06; 52(2):55-63. PubMed ID: 18380802
    [Abstract] [Full Text] [Related]

  • 8. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2010 Jan 06; 82(1):128-37. PubMed ID: 19950232
    [Abstract] [Full Text] [Related]

  • 9. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J.
    J Clin Virol; 2004 Dec 06; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [Abstract] [Full Text] [Related]

  • 10. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.
    Vaccine; 2012 Jan 05; 30(2):466-74. PubMed ID: 22051136
    [Abstract] [Full Text] [Related]

  • 11. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 12. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V, Chichester JA, Ebensen T, Schwarz K, Hartman CE, Shoji Y, Guzmán CA, Yusibov V, Sewald K, Braun A.
    Vaccine; 2014 May 30; 32(26):3216-22. PubMed ID: 24731807
    [Abstract] [Full Text] [Related]

  • 13. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H, Fujihashi K, Miyakoshi T, Yoshikawa T, Fujita-Yamaguchi Y, Kojima N, Nakata M, Suzuki Y, Tamura S, Kurata T, Sata T.
    Vaccine; 2007 Sep 28; 25(39-40):6975-80. PubMed ID: 17716790
    [Abstract] [Full Text] [Related]

  • 14. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, Yusibov V, Guzman CA, Cox RJ.
    Vaccine; 2011 Jul 12; 29(31):4973-82. PubMed ID: 21600260
    [Abstract] [Full Text] [Related]

  • 15. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.
    Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H.
    Vaccine; 2009 Sep 18; 27(41):5620-7. PubMed ID: 19647064
    [Abstract] [Full Text] [Related]

  • 16. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
    J Med Virol; 2005 Jan 18; 75(1):130-6. PubMed ID: 15543590
    [Abstract] [Full Text] [Related]

  • 17. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH, Ko HJ, Volker G, Potter AA, Mutwiri G, Babiuk LA, Kweon MN.
    Vaccine; 2010 Mar 08; 28(11):2311-7. PubMed ID: 20060944
    [Abstract] [Full Text] [Related]

  • 19. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 20. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ, Kim S, Kang CY.
    Vaccine; 2011 Jan 10; 29(3):417-25. PubMed ID: 21087689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.